Key facts
- Route 92’s last known valuation is $307.5M (Jan 2026).
- It has raised $293.6M; the latest was Later Stage VC ($50.0M) in Jan 2026.
- Notable investors include Norwest, Novo Holdings, InnovaHealth Partners, Sectoral Asset Management, The Vertical Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Route 92
- ·The full record, as it builds
Funding rounds
No funding rounds for Route 92 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Route 92
Developer of neurovascular intervention devices designed to improve outcomes for patients with vascular conditions in the brain. The company offers advanced catheter systems and reperfusion technology for precise navigation and clot removal, enabling healthcare providers to perform complex neuro-intervention procedures with improved access and treatment efficiency.
- Sector
- Healthcare
- HQ
- West Jordan, UT, United States
- Founded
- 2015
- Employees
- 189
- Website
- route92medical.com/
- Ownership
- Privately Held (backing)
Route 92 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Route 92 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Route 92 in its N-PORT filings yet. We sweep new filings monthly.